A new intravenous antibiotic that could benefit patients and help reduce pressure on hospitals is now available in the UK.
Xydalba™ (dalbavancin hydrochloride) is an IV antibiotic approved by the European Medicines Agency (EMA) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. It is the first and only option for ABSSSI that offers a complete course of IV therapy delivered as a single 30-minute infusion.
Compared to other IV antibiotics that may need to be administered for up to 14 days and can require hospitalisation, in clinical trials, Xydalba successfully treated a majority of patients as outpatients.
Xydalba’s clinical development programme also demonstrated that it was as effective and as well-tolerated as other intravenous antibiotics.
ABSSSI can be potentially life-threatening. They include conditions, such as cellulitis / erysipelas, wound infections and major skin (cutaneous) abscesses. There are more than 290,000 estimated cases of serious skin infections in the UK, with 79 per cent receiving IV antibiotics as a first-line treatment. Cellulitis accounts for eight per cent of emergency hospital admissions.
Professor David Livermore, of the Norwich Medical School (University of East Anglia), commented, ‘One- or two-dose regimens of dalbavancin have the potential to get ABSSSI patients home early and to remodel how we think of OPAT.’